Efficacy of Colistin versus β-Lactams, Aminoglycosides, and Rifampin as Monotherapy in a Mouse Model of Pneumonia Caused by Multiresistant Acinetobacter baumannii
Open Access
- 1 June 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (6) , 1946-1952
- https://doi.org/10.1128/aac.46.6.1946-1952.2002
Abstract
The treatment of life-threatening infections due to carbapenem-resistant Acinetobacter baumannii has become a serious challenge for physicians worldwide. Often, only colistin shows in general good in vitro activity against these carbapenem-resistant strains, but its antibacterial efficacy in comparison with the antibiotics most used in clinical practice is not well known. We studied the efficacy of colistin versus those of imipenem, sulbactam, tobramycin, and rifampin in an experimental pneumonia model with immunocompetent mice. We used three strains of A. baumannii corresponding to the main clones (A, D, and E) involved in the outbreaks of our hospital, with different grades of resistance to imipenem (imipenem MICs of 1, 8, and 512 μg/ml, respectively) and to the other antibiotics. The MIC of colistin was 0.5 μg/ml for the three strains. Reduction of log10 CFU/g in lung bacterial counts, clearance of bacteremia, and survival versus results with controls were used as parameters of efficacy. Imipenem and sulbactam (Δlung counts: −5.38 and −4.64 log10 CFU/ml) showed the highest level of bactericidal efficacy in infections by susceptible and even intermediate strains. Tobramycin and rifampin (−4.16 and −5.15 log10 CFU/ml) provided good results against intermediate or moderately resistant strains, in agreement with killing curves and pharmacodynamics. On the contrary, colistin showed the weakest antibacterial effect among the antibiotics tested, both in killing curves and in the in vivo model (−2.39 log10 CFU/ml; P < 0.05). We conclude that colistin did not appear as a good option for treatment of patients with pneumonia due to carbapenem-resistant A. baumannii strains. Other alternatives, including combinations with rifampin, may offer better therapeutic profiles and thus should be studied.Keywords
This publication has 48 references indexed in Scilit:
- Epidemiological characterization of hospital-acquired Acinetobacter baumannii isolates from a 1500-bed teaching hospital by phenotypic and genotypic methodsJournal of Hospital Infection, 2001
- Characterization of OXA-25, OXA-26, and OXA-27, Molecular Class D β-Lactamases Associated with Carbapenem Resistance in Clinical Isolates of Acinetobacter baumanniiAntimicrobial Agents and Chemotherapy, 2001
- Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClinical Infectious Diseases, 1999
- Successful Treatment of Ventriculitis Due to Carbapenem‐ResistantAcinetobacter baumanniiwith Intraventricular Colistin Sulfomethate SodiumClinical Infectious Diseases, 1999
- Acinetobacter species as nosocomial pathogensEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- National Nosocomial Infections Surveillance (NNIS) Report, data summary from October 1986–April 1996, issued May 1996American Journal of Infection Control, 1996
- Outbreak caused by two multi-resistant Acinetobacter baumannii clones in a burns unit: emergence of resistance to imipenemJournal of Hospital Infection, 1995
- Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactamThe Lancet, 1994
- In-vitro andin-vivo activities of antimicrobial agents againstAcinetobacter calcoaceticusJournal of Antimicrobial Chemotherapy, 1985
- Binding of Polymyxin Antibiotics to Tissues: The Major Determinant of Distribution and Persistence in the BodyThe Journal of Infectious Diseases, 1971